Functional Assessment of Pluripotent and Mesenchymal Stem Cell Derived Secretome in Heart Disease
Keywords:
[1 hydrogels for cardiac tissue repair [7,8 address this concern [12,13 [14,15].
.
2,3]. Several investigations 3–5]. However, it is unclear what 6]. This present study is a ].
9–11]. The ideal source of 16–18]. The aim of this study is to investigate the paracrine effects of stem cells on post-MI functional recovery and scar size in an ischemic rat heart model. It has been hypothesized that signaling molecules such as vascular endothelial growth factor (VEGF) and platelets derived growth factor (PDGF) present in cell secretome would have angiogenesis and neovascularization properties to improve myocardial function and reduction in scar size post MI. Bone marrow derived hMSCs and subcutaneous tissue reprogrammed cells were the stem cells used to produce HiPSCs. The main signaling molecules VEGF and PDGF, which primarily drive neovascularization and myocardial recovery, were focused on within Human bone marrow-derived hMSC’s were donated by Dr. Yen BL at the Institute of Cellular and System Medicine (Zhunan, Taiwan). The hMSC’s were isolated using HiPSCs isolated from fibroblasts within the skin of normal tissue donors and reprogrammed by episomal plasmid retroviral expression of OCT4, SOX2, KLF4 and MYV genes, were obtained from ATCC (Manassas, VA) along with all cell culture reagents. The cells were feeder-free (Pluripotent Stem Cell SFM XF/FF), and a biological matrix (cell matrix basement gel) was used in place of fibroblast feeders to provide a surface for attachment of the hiPSCs. Cells were cultured in T75 flasks in DMEM: F-12 medium. Culture medium (CM) was changed every 48 hours. Cells at 80–90% confluence were split or harvested. To split or harvest cells, the CM was aspirated, and cells were rinsed twice with 4 mL of Dulbecco’s-PBS (D-PBS). Stem cell dissociation reagent, 2 mL of 0.25% Trypsin was added and then followed by 10 to 15 minutes of incubation at 37°C in a humidified incubator at . After that, 2 mL of DMEM: F-12 with ROCK inhibitor Y27632 was added to detach the cells. Suspended cell aggregates were then centrifuged at 200xg for 5 minutes at room temperature and cells were again re suspended in 1 mL of DMEM: F12 + ROCK inhibitor, and re-plated with a total of 10 mL of CM.
CM from hMSC’s and HiPSC’s was collected for subsequent analysis prior to cell splitting when cells have reached 80–90% confluence rate. CM was collected and filtered using an Amicon® Ultra-15 Centrifugal Filter (MW 10 kDa, Merck Millipore, Billerica, MA). The aspirate secretome was centrifuged at 14000 rpm for 10 minutes and stored at −80°C. This An ELISA kit (Peprotech, rocky hill, NJ) was used to estimate the quantities of VEGF and PDGF present in each cell line’s secretome. ELISA microtiter plates were pre-coated with a murine monoclonal antibody against the media cytokine (VEGF or PDGF) being measured, following the manufacturer’s instructions. The absorbance was measured at 405 nm with wavelength correction at 650 nm within a period of 60 minutes at 15 minutes intervals.
this study.
previously described protocols [19].
5% CO and 21% O 2 2
was completed for 12 consecutive cycles.
The female Lewis rats selected were between 200–250 g in weight (Charles River Laboratories, Senneville, Canada). All animal studies were performed in accordance with the guidelines set forth by the Canadian Council on Animal Care and were approved by the The rats were anesthetized, intubated, and mechanically ventilated at 85 breaths/minute. The left coronary artery was accessed via a left thoracotomy through the fourth intercostal space and permanently ligated 2 mm from its origin with a 7/0 polypropylene suture(Ethicon Inc, Somerville, NJ). The ischemic myocardial segment rapidly became identifiable by observing pallor and akinesia corresponding to the distribution area of the left coronary artery. Fifteen minutes after ligation of the artery, 3 equal peri-infarct intramyocardial injections, totaling 500 μL, of the previously harvested MSC or HiPSC culture media or normal saline were completed using a 27-gauge needle. The experimented animals survived up to 8 weeks for analysis. The rats were randomized into three groups: (i) non-treated group (n = 10, normal saline), (ii) treatment group HiPSC (n = 10, HiPSC secretome), (iii) treatment group hMSC (n = 10, hMSC secretome). All groups had coronary ligation and injection of treatment into Trans-thoracic echocardiographic examinations were performed under inhaled isoflurane anesthesia (2.5% in oxygen, 500–700 mL/minute). Each rat had an echocardiography before surgery, to ensure baseline measurement, then immediately after ligation and at 1, 2, 4 and 6 weeks. These images were obtained using a commercially available system (Micromaxx Measurements were recorded slightly inferior to the apex of the papillary muscles of the mitral valve. The time of end-diastole was defined as time of maximum diameter of the LV in one heart cycle and end-systole was defined as the minimum diameter. Following the “leading-edge” method, two images, on average, were obtained in each view and averaged To analyze the effect of treatment, a scar area analysis was performed. After cardiac excision, the hearts were immediately immersed in saline to remove excess blood from the ventricles. Samples were fixed in neutral-buffered 4% formalin and paraffin. Paraffinembedded samples were sectioned at 5 μm. Masson’s trichrome staining (DBS, Pleasanton, CA) was performed to delineate scar tissue (blue color) from the total area of normal myocardium. Masson’s trichrome-stained sections were captured as digital images and analyzed using Image-J software (version 1.41; National Institutes of Health, Bethesda, MD) and Image Scope software (© 2016 Leica Biosystems Imaging). Infarct areas were calculated and expressed as a percentage. Samples were obtained at time points 1, 2, 4, 6, and 8 weeks. The results fromweeks 2, 4, 6 and 8 were combined to increase the sample size
institutional ethics committee.
the peri-infarct area.
P04224; SonoSite, Bothell, WA).
over three consecutive cycles.
for analysis.
Neovascularization was evaluated by analyzing the capillary and arteriole density in the peri-infarct zone. Immunofluorostaining was performed by using antibodies against CD31 (Santa Cruz Biotechnology Inc, Santa Cruz, CA) to identify capillary endothelial cells. To measure capillary density, three fields in the peri-infarct area were imaged, and the number of capillaries with diameter of 10|im or greater were counted. The capillary density (mean sections spanning the peri-infarct tissue region of each heart.
We used the rat cytokines array panel A (R &D system, Inc., Minneapolis, MN) according to the manufacturer instructions to determine the concentration of soluble cytokines in the rat’s serum. This kit allows us to measure different cytokines simultaneously, such as VEGF, fractalkine, Interleukin-3, Interferon gamma, soluble intercellular adhesion molecule −1 Values are expressed as mean±SD and/or mean ± SEM. Typically, groups were tested and performed in triplicates and were compared with the student’s t-test, or by using the multivariant analysis of variance (MANOVA) test. Results were considered significant if the Our analysis quantified VEGF and PDGF produced by were 5 groups: “MSC-CM” and “HiPSC- CM” were the conditioned media harvested from cultured MSCs and HiPSCs, respectively. While “MSC-pre” was the MSC conditioning media before cell culture (DMEM), “HiPSC-pre” was HiPSC culture media before cell culture (DMEM: F12-no rock), “HiPSC-pre-r” was HiPSC conditioning media before cell rock inhibitor (DMEM: F12-with rock).
There was a significant increase in VEGF and PDGF concentrations between each cell line and its control at 0 through 60 minutes, as shown in (Table 1). Additionally, there was a significant increase in the release of both growth factors in the HiPSC culture media compared to the MSC media at 60 minutes (PDGF: P= 0.022; VEGF: P= 0.0016).
ELISA studies reveled PDGF concentration of 3.35±(0.031) ng/ml for MSC-CM group, 3.44±(0.042) ng/ml for HiPSC-CM group, 3.2±(0.107) ng/ml for MSC-pre-group, 3.1±(0.075) ng/ml for HiPSC-pre group and 3.3±(0.047) ng/ml for HiPSC-pre-r group at 60 min in comparison to 0.68±(0.027) ng/ml for MSC-CM group, 0.78±(0.03) ng/ml for HiPSC-CM group,0.64±(0.013) ng/ml for MSC-pre-group, 0.71±(0.013) ng/ml for HiPSC- pre group and 0.71±(0.014) ng/ml for HiPSC-pre-r group at 0 min. It also showed, a VEGF concentration of 3.3±(0.051) ng/ml, 3.4±(0.024) ng/ml, 3.3±(0.03) ng/ml, 3±(0.029) ng/ml and 3±(0.017) ng/ml for MSC-CM group, HiPSC-CM group, MSC-pre group, HiPSC-pre
total CD31- positive microvessels)/mm
(SICAM-1) andL-selectin (CD62L).
p-value was < 0.05.
culture with ) was quantified using the average of three tissue in-vitro hMSCs and HiPSCs. There group and HiPSC- pre-r group respectively at 60 minutes compared to1.07± (0.020) ng/ ml, 1.1± (0.017) ng/ml, 1.01±(0.029) ng/ml, 1.012±(0.009) ng/ml and 1.014±(0.013) ng/ml for MSC-CM group, HiPSC-CM group, MSC-pre group, HiPSC-pre group and HiPSC-pre-r The animals were separated into 3 groups: NT, HiPSC and hMSC. Pre-operative echocardiography demonstrated no significant difference in LVEF or FS between the three groups (Table 2). Additionally, there was no significant difference between pre-operative LVEF or FS between the two treatment groups, where LVEF for Group HiPSC and Group hMSC (73± 2.4 vs. 73± 2.7, respectively), and FS for group HiPSC and Group hMSC (37.3±2vs. 37.4 ± 2, respectively). Following surgery, there was a rapid deterioration in both LVEF and FS means, in all groups, when compared to the pre-operative measurements (Table 2). There was no significant difference in mean LVEF or FS between groups (LVEF, NT vs. HiPSC: (34.7±3.4 vs. 35.7±2.6), NT vs. hMSC: (34.7±3.4 vs. 33.1± 4.4), hMSC vs. HiPSC: (35.7±2.6 vs. 33.1±4.4) p = 0.501; FS, NT vs. HiPSC: (14±1.6 vs. 14.8 ±1.3), NT vs. hMSC: (14 ±1.6 vs. 13.5±2), hMSC vs. HiPSC: (13.5±2 vs. 14.8±1.3). In contrast, there was a significant difference in LVEF between treatment and control groups as early as week 2 (42.7±8.1, P<0.0001) (Figure 1). Similarly, there was a significant difference in FS at weeks 2, 4, and 6 compared to baseline in both the HiPSC and hMSC groups (Figure 2). There was no significant difference in mean LVEF (2 weeks: P=0.169; 4 weeks: P=0.864; 6 weeks: P=0.942) or mean FS (2 weeks: P=0.166; 4 weeks: P=0.907; 6 weeks: P=0.893) between the two treatment groups at any In the control (NT), hMSC, and HiPSC groups, hearts were harvested after the following time points, 1, 2, 4, 6 & 8 weeks post-surgery. The scar tissue area was quantified at weeks 1, 2+ (2–4 grouped) and 6+ (6–8 grouped). There was no statistically significant difference between all groups at week 1 (P=0.385). There was a statistically significant decrease in scar area in hMSC and HiPSC groups compared to the NT group (Figure 3) at weeks 2–4 (NT vs. hMSC: (33±0.01 vs. 26 ±0.01; P=0.001); NT vs. HiPSC: (33±0.01 vs. 23.25±0.009; P< 0.0001) and 6–8 (NT vs. hMSC: (34.3±0.011 vs. 22.6±0.016; P<0.0001); NT vs. HiPSC: (34.3±0.011 vs. 19.8±0.017; P<0.0001). Furthermore, at 2–4 weeks post-surgery, there was significant reduction in scar area in the hMSC group compared to the HiPSC group, with mean difference of 24.42 ±1.7, P=0.014. It was also evident at weeks 6–8, with mean difference of (21±2.1, P=0.024 (Figure 3). Histological demonstration of the reduction in scar size in response to treatment is shown in (Figure 4).
Immuno fluorescent staining was performed to assess CD31 staining in endothelial cells at the peri-infarct zone. Each group was again divided into 3 timeframes: week 1 (postoperative), week 2+ (weeks 2–4) and week 6+ (weeks 6–8) (figure 5). A significant increase in peri-infarct angiogenesis in the HiPSC and hMSC groups was found compared to controls at weeks 2+ (hMSC vs NT: (37.4±6.9 vs. 23±3.7) with mean difference of (29.5±9), group respectively at 0 minutes.
immediately following surgery pre-determined time point.
P=0.003, HiPSC vs. NT: (39.2±11.5 vs. 23± 3.7) with mean difference of (32.7±12), P=0.006) and weeks 6+ (hMSC vs NT: (40.9 ± 14 vs. 17.6±8), with mean difference of (32±16), P<0.0001, HiPSC vs. NT: (48.8±11.4 vs. 17.6 ± 8) with mean difference of (37.6±18), P<0.0001). There was no significant difference in angiogenesis between the HiPSC and hMSC groups at weeks 2+ (39.2±11.5 vs. 37.4±6.9), with mean difference of (38.5±9.8), P=0.72 or 6+ (48.8±11.4 vs. 40.9 ±14), with mean difference of (45±13), P=0.097.The numbers here represented as cells/field.
The proteomics analysis (Figure 6) revealed abundant presence of VEGF, fractalkine and Interleukin-3 in the serum of group HiPSC that was absent in the NT and hMSC groups. Among the other factors detected in HiPSC group, a higher concentration of VEGF, 1and L-select in (CD62L) were detected.
Although the use of stem cell-based therapy has shown a promise in the treatment of MI and CHF, the benefits remains limited and associated with significant side effects [ this present study, the potential role for cytokines to initiate myocardial repair in infarcted myocardial tissue was assessed, and a cell lineage capable of producing the cytokines VEGF and PDGF, was identified. The key findings were: i) both HiPSCs and hMSCs secrete VEGF in vitro environment; ii) injection of the culture medium from both cell types containing these cytokines into peri-infarcted tissue resulted in improved LVEF and FS, post MI in the LAD territory; iii) stem cells secrete a number of other growth factors and chemokines that may improve cardiac function post-MI.
Based on the initial hypothesis of the paracrine effect of stem cells, the focus was on VEGF and PDGF given their direct relationship to angiogenesis and neovascularization [ Notably, both VEGF and PDGF also demonstrate some adverse effects. When administered in high intravenous doses, they could potentially lead to tumor pathogenesis and organ ]. However, both substrates were used in a localized fashion, with direct injection into the peri-infarct tissue. Measurable amounts of VEGF and PDGF were detected in the culture media postinjection of HiPSCs and hMSCs, which improved the myocardial remodeling properties associated with experimental models of MI.
The media from both stem cell lines were injected into the peri-infarct area rather than grafting the stem cells since previous investigations have demonstrated teratogenicity and arrhythmia disturbances with stem cell transplantation [ scar area, increase in peri-infarct angiogenesis, and improved LVEF and FS using this technique was achieved. The results are also comparable to other investigations using stem cell grafting techniques which showed improved cardiac function following MI or ischemic The CD-31 immunostaining showed significantly more peri-infarct vascularization in hMSC or HiPSC culture media treated rats compared to the non-treated. In corroboration with echocardiographic results, these findings are consistent with those of Schuleri and
SICAM-
and PDGF in an fibrosis [26,27 cardiomyopathy [30].
20,21]. In 22–25].
15,28,29]. Overall, a reduction in colleagues, who identified post-infarct porcine hearts grafted with hMSCs had an increase in myocardial blood flow in infarcted tissue and suggested that this may reduce apoptosis and ]. This may explain the small scar size identified in rat hearts treated with hMSC and HiPSC culture medium at 6–8 weeks post-infarct. Although, the exact mechanism is unknown, itis hypothesized to be from the improvement of blood supply in the peri-infarct myocardium or possibly from the recruitment of cardiomyocyte progenitor A higher presence of VEGF, interleukin-3 (or multi-colony stimulating factor) and fractalkine was detected in rats treated with HiPSCs conditioned media. Several investigations have demonstrated the effect of these cytokines on cellular proliferation, differentiation, maturation, angiogenesis, and cardiac remodeling. Interleukin-3 has demonstrated improvement in left ventricular function and survival in animal models with acute MI or ischemic cardiomyopathy [ the enlargement of ventricular chambers following MI [ cytokine-induced neutrophil chemoattractant-1 (CINC-1), SICAM-1, and L-selectin were also detected in HiPSC culture media treated rats compared to the NT group. CINC-1 acts as a chemoattractant for polymorphonuclear neutrophils (PMNs) to the peri-infarct areas by interacting with cell surface chemokine receptors [ have demonstrated roles as chemoattractant and in neutrophil function [ Since ischemic cardiomyopathy continues to remain a prominent cause of morbidity and mortality worldwide, investigation of stem cell therapy to improve cardiac function will continue. This stem-cell based therapy exploits the paracrine effect of stem cells to promote cardiac angiogenesis, reduce scar area, and improve cardiac function by minimizing some adverse effects associated with stem cell grafting. Translated to the clinical setting, these findings also suggest that secretome from hMSC and HiPSC can be prepared and made available on the shelf and potentially used in patients with acute MI and or ischemic cardiomyopathy. Therefore, it eliminates the logistics of highly specialized institutes and complex harvesting, proliferation and implantation processes while offering the benefits of stem cell-based therapy to the generalized population. Future studies aimed at characterizing the secretory profile of cell-based therapy may provide target specific treatment for patient This research is supported in-part by FRSQ-The Cell grant for Dr. D Shum-Tim.
In-part supported by NSERC discovery grant for Dr. Adel Schwertani, In-part supported by King Faisal specialist hospital and research center for Dr M Alrefai, Arghya Paul, acknowledges the Institutional Development Award (IDeA) from the National Institute of General Medical Sciences, National Institutes of Health (NIH), under Award Number P20GM103638, University of Kansas New Faculty General Research Fund, and Umbilical Cord Matrix Project fund from State of Kansas.
American Type Culture Collection improve cardiac function [31 cells.
with MI and CHF.
32,33]. Fractalkine plays a role in delaying 34]. Higher concentrations of 35]. Finally, SICAM-1 and L-selectin 36,37].
Horseradish Peroxidase Cytokine Induced Neutrophil Chemo-Attractant Left Ventricle End-Diastolic Diameters Left Ventricle End-Systolic Diameters Left Ventricular End- Diastolic Volume Left Ventricular End-Systolic Volume Soluble Intercellular Adhesion Molecule-1 Octamer Binding Transcription Factor-4 Sex Determining Region Y-Box 2 Kruppel Like Factor-4 1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380(9859): 2095–2128. [PubMed: 23245604] 2. Bergmann O, Bhardwaj RD., Bernard S, Zdunek S, Barnabé-Heider F, Walsh S, et al. (2009) Evidence for cardiomyocyte renewal in humans. Science, 324(5923): 98–102. [PubMed: 19342590] 3. Beltrami AP., Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, et al. (2001) Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med, 344(23): 1750–1757.
4. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA., Anversa P (1998) Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A, 95(15): 8801–8805. [PubMed:
5. Meckert PC., Rivello HG, Vigliano C, Gonzalez P, Favaloro R, Laguens R (2005) Endomitosis and polyploidization of myocardial cells in the periphery of human acute myocardial infarction. Cardiovasc Res, 67(1): 116–123. [PubMed: 15949475] 6. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM., Li B, et al. (2001) Bone marrow cells regenerate infarcted myocardium. Nature, 410(6829): 701–705. [PubMed: 11287958] 7. Waters R, Pacelli S, Maloney R, Medhi I, Ahmed RP., Paul A (2016) Stem cell secretome-rich nanoclay hydrogel: a dual action therapy for cardiovascular regeneration. Nanoscale, 8(14): 7371– 8. Paul A, Hasan A, Kindi HA., Gaharwar AK, Rao VT, Nikkhah M, et al. (2014) Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair. ACS 9. Traverse JH., Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al. (2012) Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. Jama, 308(22): 2380–2389. [PubMed:
10. Sürder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, et al. (2013) Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation, 127(19): 1968–1979. [PubMed: 23596006] 11. Perin EC., Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, et al. (2012) Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA,
